According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company’s research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. “
Several other research firms have also recently weighed in on IGXT. Maxim Group reiterated a “buy” rating and set a $1.50 price objective on shares of IntelGenx Technologies in a research report on Friday, August 9th. ValuEngine upgraded shares of IntelGenx Technologies from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $1.00 price objective on shares of IntelGenx Technologies in a report on Monday. Finally, Echelon Wealth Partners restated a “buy” rating and set a $1.60 price objective on shares of IntelGenx Technologies in a report on Tuesday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $1.37.
IntelGenx Technologies (OTCMKTS:IGXT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). IntelGenx Technologies had a negative net margin of 792.90% and a negative return on equity of 162.47%. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.20 million. Analysts predict that IntelGenx Technologies will post -0.11 earnings per share for the current fiscal year.
IntelGenx Technologies Company Profile
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.
Read More: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.